Acute Kidney Injury (AKI) Therapeutics Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

According to a new research report “Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, AKI therapeutics currently exhibits a proliferating pipeline of 39 therapeutic candidates. 

AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system. Dehydration, abdominal pain, rise in blood pressure, mild back pain, and vomiting are some of the symptoms associated with the disease.

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage with this administration includes entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for AKI through intravenous route has shown promising results in clinical studies.

Request to Get Free Sample Pages at:                                                                                                                                                    https://www.pharmaproff.com/request-sample/1253

In November 2018, Angion Biomedica Corp. and Sinovant Sciences HK Limited entered into a collaboration and license agreement for the development of ANG-3777 for the treatment of patients with delayed graft function (DGF) following kidney transplantation and AKI following open-heart surgery requiring cardiopulmonary bypass.

Similarly, in May 2016, A1M Pharma AB collaborated with CSL Behring LLC to investigate the potential of combination therapy of Alpha 1 Microglobulin (A1M) and plasma protein in patients suffering from pre-eclampsia and AKI. The endogenous protein A1M is expected to showcase several protective mechanisms in tissues.

Sentien Biotechnologies Inc., AM-Pharma B.V., and Quark Pharmaceuticals Inc., are some other major companies involved in the development of drug candidates for the treatment of AKI.

AKI Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Read More

Achondroplasia Therapeutics Pipeline Analysis -Drug Profile, Top Industry Intelligence and Therapeutic Development

Achondroplasia therapeutics currently exhibits a considerably strong pipeline with seven active drug candidates.

Achondroplasia is a common disorder of dwarfism with disproportionate stature. It is an autosomal dominant disorder that occurs due to mutation in fibroblast growth factor receptor 3 (FGFR3) gene, which is located on short arm of chromosome 4. The disorder is characterized by macrocephaly, shortened-limbs (rhizomelic dwarfism), midface retrusion, and frontal bossing. The achondroplasia therapeutics pipeline study covers seven active drug candidates in different stages of development.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/achondroplasia-therapeutics-pipeline-analysis

Achondroplasia therapeutics pipeline has majority of candidates in the Pre-Clinical stage of development. A peptide-based drug candidate namely, vosoritide, is in the Phase III stage of development by BioMarin Pharmaceutical Inc., for the treatment of achondroplasia.

The drug candidates developed by several companies for the treatment of achondroplasia have shown positive clinical results in the various phases of drug development. For instance, BioMarin Pharmaceutical Inc.’s drug candidate vosoritide, which is under the Phase III stage of development, has been well-tolerated at all doses in the Phase II stage’s study. The majority of adverse events (AEs) were mild and no serious AEs were reported during the study. Across all doses, injection site reactions and hypotension were the most common drug-related AEs.

Request to Get the Sample Pages at:  

                                               https://www.pharmaproff.com/request-sample/1153

Technological Advancements is a key factor marking the Growth of Achondroplasia Therapeutics Pipeline

It has been observed that many pharmaceutical companies are adopting advanced technologies for the development of achondroplasia therapeutics. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. For instance, RIBOMIC Inc.’s, RiboART system, is the essential element in drug discovery technology, that helps in the discovery of various new drugs for the treatment of the various diseases including achondroplasia.

Some of the key players involved in the development of achondroplasia therapeutics include BioMarin Pharmaceutical Inc., Ascendis Pharma A/S, and Therachon AG.

Achondroplasia Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Read More

Tardive Dyskinesia Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations

Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor blocking drugs which are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/tardive-dyskinesia-therapeutics-pipeline-analysis

The reasons that some people who take these drugs may get TD, and some people do not, is unknown. Tardive dystonia is a more severe form of TD in which slower twisting movements of the neck and trunk muscles are prominent.

Request to Get the Sample Pages at: 

                                                               https://www.pharmaproff.com/request-sample/1106

The typical symptoms of TD include facial grimacing, sticking out the tongue, and sucking or fish-like movements of the mouth. INGREZZA (valbenazine), developed by Neurocrine Biosciences Inc., is one of the key drugs developed for the treatment of TD.

The drug candidates in TD pipeline include, but not limited to, SOM3355 and MT-5199. Some of the companies having drugs in the TD pipeline includes SOM INNOVATION BIOTECH, SL, and Mitsubishi Tanabe Pharma Corporation.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Major Depressive Disorder Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents

Major depressive disorder, also known as the clinical depression, is characterized by a constant sense of despair and hopelessness. It usually affects daily activities such as study, sleep, and eating.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/major-depressive-disorder-therapeutics-pipeline-analysis

Common symptoms observed in major depressive disorder are fatigue, indecisiveness, impaired concentration, feelings of worthlessness or guilt, insomnia or hypersomnia, restlessness, significant weight loss or gain and recurring thoughts of death or suicide.

Request to Get the Sample Pages at: 

                                                              https://www.pharmaproff.com/request-sample/1105

According to the National Institute of Mental Health, an estimated 16.1 million adults aged 18 or older in the U.S. had at least one major depressive episode in 2014.

VistaGen Therapeutics Inc. is developing AV-101, a new generation oral antidepressant, for the treatment of major depressive disorder. NeurOp Inc., and ACADIA Pharmaceuticals Inc. are some other key players involved in the development of drugs for the treatment of major depressive disorder. 

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Lewy Body Dementia Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations

Lewy body dementia is a progressive brain disorder in which Lewy bodies build up in different parts of the brain that regulate cognition, movement and behavior. Lewy bodies are abnormal deposition of a protein called alpha-synuclein. The symptoms associated with the Lewy body dementia includes memory and thinking problems; moving problems; and sleeping and behavioral changes. It can be treated by medications, physical therapy, speech therapy, occupational therapy, and individual and family psychotherapy.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/lewy-body-dementia-therapeutics-pipeline-analysis

Axovant Sciences Ltd. is in the process of developing a combination of RVT-103 and RVT-104 for the treatment of Lewy body dementia. Asceneuron SA, and Arena Pharmaceuticals Inc. are some other key players involved in the development of drugs for the treatment of Lewy body dementia.

Request to Get the Sample Pages at: 

https://www.pharmaproff.com/request-sample/1104

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Ischemia Reperfusion Injury Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations

Ischemia reperfusion injury is a medical condition which involves tissue injury, resulting in the interruption of blood supply, and occurs when the blood supply to an area of tissue is cut off. Ischemia-related tissue injury can occur in various organs including heart and brain.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/ischemia-reperfusion-injury-therapeutics-pipeline-analysis

During reperfusion injury, inflammatory responses occur including release of free radicals, vascular leakage, recruitment of inflammatory cells, and proteins that cause tissue destruction. Currently there are no available drug therapies but surgeries are available to remove the blood clot responsible for restricted blood flow.

Request to Get the Sample Pages at: 

                                        https://www.pharmaproff.com/request-sample/1143

Radikal Therapeutics is in the process of developing R-190 as a new chemical entity for the treatment of limb ischemia reperfusion injury. Some of the companies having a pipeline of ischemia reperfusion injury include Catalyst Biosciences Inc. and NovelMed Therapeutics Inc. among others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Infertility Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Infertility is defined as the biological inability to conceive or contribute to conception, after having regular unprotected sex. According to the data published by the Department of Health and Human Services, approximately 10% to 15% of couples in the U.S. are infertile and have not conceived after at least one year of regular, unprotected sex.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/infertility-therapeutics-pipeline-analysis

Infertility may have a single cause in one of the partners, or it could be the result of a combination of factors. Some of the causes of infertility are ovulation disorders in women, chemotherapy, radiotherapy, use of illegal drugs, and testicular infections in men. 

Request to Get the Sample Pages at: 

                                                   https://www.pharmaproff.com/request-sample/1142

Risk factors associated with infertility are smoking, alcohol consumption, obesity, eating disorders, over-exercising, inactivity, sexually transmitted infections (STIs), mental stress, and exposure to some chemicals. Ferring International Center S.A. is in the process of developing FE 999310, for the treatment of infertility. Some of the companies having a pipeline of infertility include CellOxess LLC, TocopheRx, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hypoxic-Ischemic Encephalopathy Therapeutics - Pipeline Analysis , Clinical Trials & Results

Hypoxic-ischemic encephalopathy is a serious birth complication that causes obstruction in blood flow in brain during the prenatal, intrapartum or postnatal period. This leads to death of the child or mental disabilities in the first two years of age.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/hypoxic-ischemic-encephalopathy-therapeutics-pipeline-analysis

Although, the cause of the disease is not yet identified but some conditions like cord prolapse, abruptio placenta, placenta previa, uterine rupture, breech presentation, maternal hypotension, or shoulder dystonia are known to be observed in the patients with this disease. Some of the symptoms observed in children with this disease are low heart rate, bluish skin colour, poor muscle tone, and excessive acid in the blood.

Request to Get the Sample Pages at: 

                                      https://www.pharmaproff.com/request-sample/1141

Celgene Corporation is in the process of developing HPDSC as a cell therapy for the treatment of hypoxic-ischemic encephalopathy. Assiut University is in the process of developing erythropoietin for the treatment of hypoxic-ischemic encephalopathy. Further, GW Pharmaceuticals is also involved in the pipeline for hypoxic-ischemic encephalopathy.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. 

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hypoxia Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents

Hypoxia is a condition characterized by inability of the tissues to receive an adequate oxygen supply. This condition is categorized into four types; hypoxic, stagnant, anaemic, fulminating, and histotoxic hypoxia. Hypoxic hypoxia is defined as the lack of oxygen in the arterial blood while in stagnant hypoxia, the rate at which blood circulates in the body is decreased.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/hypoxia-therapeutics-pipeline-analysis

Fulminating hypoxia is an induced type of hypoxia through inhalation of undiluted inert gases. The lack of the haemoglobin causes less intake of oxygen in the blood, resulting in the development of anaemic hypoxia. Histotoxic hypoxia occurs due to cyanide poisoning, in which the tissues are unable to accept oxygen from capillaries.

Request to Get the Sample Pages at: 

                                       https://www.pharmaproff.com/request-sample/1140

Global Blood Therapeutics Inc. is in the process of developing GBT440 as an abnormal haemoglobin modulator for the treatment of hypoxia. NuvOx Pharma LLC is in the process of developing NVX-108 for the treatment of hypoxia. Akebia Therapeutics Inc. is also involved in the pipeline for Hypoxia.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Hypoxia-Inducible Factor (HIF) Inhibitor Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents,

Hypoxia-inducible factor (HIF) inhibitor inhibits the HIF mediated hypoxic responses. HIF is a transcription factor that activate when there is a decrease in the availability of oxygen in the cellular environment. Hypoxia promotes the formation of blood vessels and this homeostatic system is required in formation of vascular system in the embryo.

Access More About This Research at:

https://www.pharmaproff.com/report/hif-inhibitor-therapeutics-pipeline-analysis

In conditions like wounds, hypoxia mediate the migration of keratinocytes and restores the epithelium. According to the researchers, the HIF plays a vital role in the development of human body, as they are required by the body to adapt in low oxygen concentration and maintain the metabolism. The therapeutic candidate which acts as an HIF inhibitor has been found to improve the symptoms in anemia, inflammatory disorders and cancer.

Request to Get the Sample Pages at: 

                                                              https://www.pharmaproff.com/request-sample/1139

In addition, HIF inhibitor have also been found to increase the erythropoietin expression and enhance hippocampal memory. In addition, HIF is also essential for immunological responses and is a key physiological regulator of homeostasis, vascularization, and anaerobic metabolism.

Company like FibroGen Inc. is developing roxadustat as a HIF prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD) and myelodysplastic syndrome (MDS).

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hyperphosphatemia Therapeutics - Pipeline Analysis , Clinical Trials & Results

Hyperphosphatemia is a medical condition which involves increased level of serum phosphate concentration in the blood. Phosphate is required for bone and cell formation, genetic coding and energy metabolism.

Access More About This Research at:

https://www.pharmaproff.com/report/hyperphosphatemia-therapeutics-pipeline-analysis

An individual is said to have hyperphosphatemia, if the phosphate concentration increasing beyond > 4.5 mg/dL (> 1.46 mmol/L).  Similar to calcium, vitamin D is required to properly absorb phosphate. The various causes of hyperphosphatemia include excessive intake of phosphate, inadequate excretion of phosphates, hypothyroidism, high vitamin D levels, and injuries causing muscle damage.

Request to Get the Sample Pages at: 

                                                        https://www.pharmaproff.com/request-sample/1138

Signs and symptoms associated with the hyperphosphatemia include renal osteodystrophy, secondary hyperparathyroidism and ectopic calcification. Hyperphosphatemia can be treated with phosphate binders, vitamin D analogs, and dietary restriction of phosphate.

Chugai Pharmaceutical Co. Ltd. is developing EOS789 as an oral formulation for the treatment of hyperphosphatemia. Some of the other companies developing hyperphosphatemia therapeutics include Ardelyx Inc., and OPKO Health Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics

Prostate cancer occurs when cells in prostate glands grow uncontrollably. Prostate is an exocrine gland that makes the fluid part of semen and lie below the bladder in front of the rectum. As per the National Institute of Health (NIH), 10.7% of all new cases of cancer in the U.S. are of prostate cancer.

Access More About This Research at:

https://www.pharmaproff.com/report/hormone-refractory-prostate-cancer-therapeutics-pipeline-analysis

Moreover, according to the National Cancer Institute, prostate cancer is the second leading cause of cancer deaths in men. The symptoms of the disease include frequent urination, difficulty in holding urine, painful or burning sensation while urinating, blood in the urine, blood in semen, erectile dysfunction, and pain in the lower back or pelvis or thighs. The treatment options for prostate cancer include hormone therapy, chemotherapy and vaccine treatment.

Request to Get the Sample Pages at: 

                                                              https://www.pharmaproff.com/request-sample/1137

The drug candidates of hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline include, but not limited to, AT-001 and Rucaparib. Some of the companies having drugs in the hormone refractory (castration resistant, androgen-independent) prostate cancer pipeline includes GTx Inc., Immunomedics Inc., and Clovis Oncology Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Hormonal Replacement Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations

Hormonal replacement therapy is a type of treatment wherein patients receive a course of hormones in order to get relieve from the menopause related problems. The therapy involves administration of synthetic estrogen and progesterone to overcome decreasing hormone level of women.

Access More About This Research at:

      https://www.pharmaproff.com/report/hormonal-replacement-therapeutics-pipeline-analysis

The most common signs and symptoms observed in patients with decreased hormone level are irregular menstrual cycles, and psychological symptoms (mood swings, anxiety, and urogenital symptoms). Venous thromboembolism, stroke, breast cancer, Alzheimer’s disease and gall bladder related disorders are some of the major adverse effects of hormonal replacement therapeutics.

Request to Get the Sample Pages at: 

                                                        https://www.pharmaproff.com/request-sample/1136

Evestra Inc. is developing EC508 hormone replacement therapy for fertility related problems. Novo Nordisk A/S is another key player involved in development of hormone replacement therapy.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis , Clinical Trials & Results

Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.

Access More About This Research at:

https://www.pharmaproff.com/report/hefh-therapeutics-pipeline-analysis

A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature cardiovascular diseases. About 1 in 250 people around the world have HeFH and only about 10% of people with this medical condition have been diagnosed.

Request to Get the Sample Pages at: 

                                                  https://www.pharmaproff.com/request-sample/1135

Diagnosis is important because there are several early aggressive treatments available which can lower the risk for heart diseases or stroke.

The drug candidates of HeFH pipeline include, but not limited to, GEM-201 and anacetrapib. Some of the other companies having drugs in the HeFH pipeline includes Gemphire Therapeutics Inc. and Merck & Co. Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Hematopoietic Stem Cell (HSC) Mobilization Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Mobilization is the recruitment of hematopoietic stem cells (HSC) into peripheral blood from the bone marrow following chemotherapy treatment. There are several advantages for reinfusion of autologous mobilized peripheral blood stem cells over bone marrow HSC.

Access More About This Research at:

https://www.pharmaproff.com/report/hsc-mobilization-therapeutics-pipeline-analysis

Some of the major advantages include enhanced immune reconstitution, shorter duration of granulocytopenia, shorter hospital stays, reduced morbidity and mortality and saving of financial resources.

Request to Get the Sample Pages at: 

                                                 https://www.pharmaproff.com/request-sample/1134

Several factors, such as type and dose of cytokines, age, mobilizing chemotherapy regimen, interval from last chemotherapy cycle and type of previous chemotherapy cycles or radiation, affects HSC mobilization. BioLineRx Ltd. is developing BL-8040, a short peptide which acts as a CXCR4 antagonist, for the treatment of HSC mobilization. Celldex Therapeutics Inc., and Aviara Pharmaceuticals Inc. are some other key players having pipeline drugs for HSC mobilization.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics - Pipeline Analysis, Clinical Trials & Results,

Globoid cell leukodystrophy, also known as Krabbe disease, is a genetic disorder which is characterized by decreased production of galactocerebrosidase. The symptoms observed during Krabbe disease are fever, vomiting, loss of head control, irritability and excessive crying, seizures, poor coordination of movement or stiffness, muscle spasms, changes in muscle tone, deterioration of motor function, difficulty walking and muscle weakness.

Access More About This Research at:

https://www.pharmaproff.com/report/globoid-cell-leukodystrophy-therapeutics-pipeline-analysis

There is no cure for Krabbe disease, however, hematopoietic stem cell transplant (HSCT) has demonstrated some positive effects on the disease. Moreover, patient’s quality of life can be improved by anticonvulsant medication to stop seizures, muscle relaxer drugs, physical therapy to help slow deterioration of muscles and occupational therapy.

Request to Get the Sample Pages at: 

                                                                    https://www.pharmaproff.com/request-sample/1133

MediciNova Inc. is developing MN-166 (ibudilast) as a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity for the treatment of Krabbe disease. BioXcel Corporation, and Zymenex A/S are some other key players involved in the development of therapeutics for Krabbe disease.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Female Sexual Dysfunction (FSD) Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Female sexual dysfunction (FSD) prevents the females to experience satisfaction from the sexual activity. FSD can be developed during any phase of the sexual response cycle which consists of excitement, plateau, orgasm and resolution phases.

Access More About This Research at:

                                        https://www.pharmaproff.com/report/fsd-therapeutics-pipeline-analysis

Sexual dysfunction is more common in women than in men. There are several medical conditions including heart diseases, diabetes, hormonal imbalances, neurological diseases, kidney diseases, alcohol consumption, depression, anxiety and drug abuse that leads to FSD.

Request to Get the Sample Pages at: 

                                                          https://www.pharmaproff.com/request-sample/1132

There are several problems associated with FSD such as inhibited sexual desire, inability to become aroused, lack of orgasm and painful intercourse. S1 Biopharma Inc. is developing LOREXYS as an oral, non-hormonal, fixed-dose combination of two antidepressants (bupropion and trazodone) for the treatment of hypoactive sexual desire disorder (HSDD) in women. Acerus Pharmaceuticals Corporation, and Palatin Technologies Inc. are some other key players having pipeline products for the treatment of FSD.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Female Contraception Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Female contraception prevents unwanted or unintended pregnancy. When the matured egg cell leave the ovary and ovulation begins, the chances of becoming pregnant increases. The main advantage of using contraceptives is reduction in menstrual bleeding and period pain.

Access More About This Research at:

https://www.pharmaproff.com/report/female-contraception-therapeutics-pipeline-analysis

Non-hormonal contraceptives have less side-effects in women as compared to hormonal contraceptives. Some of the disadvantages observed in women using hormonal contraceptives are sore breast, nausea, headache, and thrombosis.

Request to Get the Sample Pages at: 

https://www.pharmaproff.com/request-sample/1131

Agile Therapeutics Inc. is in the process of developing AG200 as an estrogen receptor agonist for female contraception. Viramal Limited is another key player developing therapeutics for female contraception related medical conditions.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Epidermolysis Bullosa (EB) Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations

Epidermolysis bullosa (EB), is a rare genetic connective tissue skin disorder that causes blisters and allows skin to become fragile. Blisters and areas of skin loss (erosions) occur in response to minor injury or friction, such as rubbing or scratching. The disease affects 1 out of every 20,000 births in the U.S. The symptoms of epidermolysis bullosa are redness and heat around an open area of skin; crusting on the wound surface; pus or yellow fluid discharge; red line or streak under the skin that spreads away from the blistered area; wound; and fever or chills.

Request to Get the Sample Pages at: 

https://www.pharmaproff.com/request-sample/1130

Epidermolysis bullosa can be diagnosed through skin biopsy, prenatal and genetic testing. In order to treat the disease, surgical treatment or rehabilitation therapy can be opted. It can also be managed by daily wound care, pain management, and protective bandaging.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/eb-therapeutics-pipeline-analysis

The drug candidates of epidermolysis bullosa pipeline include, but not limited to, EB 101, FCX 007, and Diacerein. Some of the companies having drugs in the epidermolysis bullosa therapeutics pipeline includes Abeona Therapeutics Inc., TWi Pharmaceuticals Inc. and Fibrocell Science Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More

Dental Pain Therapeutics - Pipeline Analysis, Clinical Trials & Results

Dental pain, also known as odontogenic pain or tooth pain, arises from the teeth or their supporting structures which includes mucosa, gingivae, maxilla, mandible, or periodontal membrane.

Request to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1129

The primary location of the reflected pain (orofacial pain) is the spinal core of trigeminal system. The trigeminal nerve provides sensory and motor innervation to the scalp, face, and mouth. Pulpal pain, periodontal pain, gingival pain, and bone pain are different types of pain originates from the dental area. Moreover, post-endodontic surgery pain, one of the severe types of pain, occurs due to apicectomy or root canal therapy.

Access Detailed Report Summary: https://www.pharmaproff.com/report/dental-pain-therapeutics-pipeline-analysis

Pericoronitis is an inflammation of soft tissues and is the common cause for removal of wisdom teeth. Percussion test, probing, pulp sensitivity test, palpation, mobility test, sinus formation, and radiographic examination are some of the most common test used to diagnose dental problems.

Stony Brook University, and Antibe Therapeutics Inc. are some of the key companies and universities involved in development of dental pain therapeutics. Antibe Therapeutics Inc. is developing ATB-352 for the treatment of dental pain.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More